Soft Impact

Underwhelmed by the proposed acquisition of Impact Biomedicines Inc. by Celgene Corp. (NASDAQ:CELG), buysiders hope to see the big biotech further expand its revenue base beyond Revlimid lenalidomide through additional deals in the near term.

“Celgene has to address the future Revlimid patent cliff which has been exacerbated after recent late-stage pipeline setbacks,” said Ailsa Craig of International Biotechnology Trust plc.

Revlimid, which is expected to lose exclusivity in the mid-2020s, has accounted for more than 55% of Celgene’s total annual revenue since 2007.

“Celgene has to...